Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Dana-Farber Cancer Institute
RenJi Hospital
The Netherlands Cancer Institute
Queen Mary University of London
NiKang Therapeutics, Inc.
British Columbia Cancer Agency
The Netherlands Cancer Institute
University of California, Irvine
Promontory Therapeutics Inc.
National Institutes of Health Clinical Center (CC)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Sheba Medical Center
Catalysis SL
Medipol University
NanOlogy, LLC
Tianjin Medical University Second Hospital
Herlev and Gentofte Hospital
Jiangsu Cancer Institute & Hospital
Jiangsu Cancer Institute & Hospital
M.D. Anderson Cancer Center
Celldex Therapeutics
NanOlogy, LLC
Belgian Gynaecological Oncology Group
Cedars-Sinai Medical Center
Novartis
Dendreon
Steba Biotech S.A.
Pierre Fabre Medicament
Sir Mortimer B. Davis - Jewish General Hospital
Steba Biotech S.A.
Eli Lilly and Company
Pharmacyclics LLC.